Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial (ASTUTE)
This trial will be starting imminently after research and clinical operations resume following the COVID19 pandemic.
Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis (Humboldt)
The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis in participants failing treatment for active noninfectious uveitis.
Web Summary here
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (MERIT)
The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6 month clinic visit. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week
Web Summary here
Artificial Intelligence to Improve Diagnosis and Treatment of Birdshot Uveitis
The National Birdshot Research Network is open to anybody who is interested in supporting patients and research with BCR.
An important part of this project will involve creating a new birdshot image-bank lined to the UK Birdshot Registry and Biobank, which will be essential for this research as well as accelerating future research into this rare condition. This will support human and artificial intelligence in developing tools for diagnosis and monitoring. This has been rolled out to sevent centres, though any centre which wishes to engage may do so.
Press release (Fight for sight) here
Thank you to those who participated in recruitment for the OSTRICH Study. This is a cross-sectional survey by several Uveitis teams belonging to the National Uveitis Clinical Study Group in the UK to understand how much steroid we prescribe in all forms. We know that this is information that both specialists and patients want and will help us formalise guidance in this area of practice. This audit opened on November 12 2018 and closed in early 2019.